- Conditions
- IgA Nephropathy
- Interventions
- BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses, Placebo Multiple Doses
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Northridge, California • Denver, Colorado • Orlando, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 4,209
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Implant
- Interventions
- Teriparatide, Placebo
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Tobacco Use
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 19
- States / cities
- La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
- Conditions
- Neuroma
- Interventions
- onabotulinum toxin type-A, placebo, 2nd phase - onabotulinum toxin type-A
- Drug · Other
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Engensis, Placebo
- Biological · Other
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Amenorrhea
- Interventions
- r-metHuLeptin, Oral Contraceptive Pills (OCPs), Placebo
- Drug · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 15
- States / cities
- Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
- Interventions
- autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Human Immunodeficiency Virus
- Interventions
- 10-1074-LS, 3BNC117-LS
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemodialysis
- Interventions
- CR845 0.5 mcg/kg, Placebo
- Drug · Other
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Bridgeport, Connecticut • Hartford, Connecticut • Kansas City, Kansas + 2 more
- Conditions
- Healthy Participants
- Interventions
- UCB9741, Placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Interventions
- Berobenatide, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Cullman, Alabama • Riverside, California • Bradenton, Florida + 3 more
- Conditions
- Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
- Interventions
- Benralizumab 30 mg, Matched placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 15
- States / cities
- Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
- Interventions
- Caplacizumab, Placebo
- Biological
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more
- Conditions
- Arthritis, Shoulder Pain
- Interventions
- intra-articular botulinum toxin type a
- Drug
- Lead sponsor
- Minneapolis Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acute Ischemic Stroke (AIS)
- Interventions
- Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels)
- Drug
- Lead sponsor
- Silver Creek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more
- Conditions
- Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more
- Conditions
- Influenza
- Interventions
- AVI-7100 versus placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Interventions
- NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg, Placebo Comparator
- Drug · Other
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Fairway, Kansas • Worcester, Massachusetts • St Louis, Missouri + 4 more
- Conditions
- Influenza
- Interventions
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 841 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more
- Conditions
- Healthy
- Interventions
- Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
- Biological
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 329 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
- Conditions
- Healthy Volunteers
- Interventions
- Placebo, MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3, MEDI5884 Dose 4
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Plaque Psoriasis
- Interventions
- ABT-874, etanercept, placebo
- Biological · Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more